The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Abstract
Several studies have demonstrated unequivocally that certain nonsteroidal anti‐inflammatory drugs (NSAIDs) such as sodium salicylate, sulindac, ibuprofen, and flurbiprofen cause anti‐inflammatory and antiproliferative effects independent of cyclooxy‐genase activity and prostaglandin synthesis inhibition. These effects are mediated through inhibition of certain transcription factors such as NF‐κB and AP‐1. The respective NSAIDs might interfere directly with the transcription factors, but their effects are probably mediated predominantly through alterations of the activity of cellular kinases such as IKKß, Erk, p38 MAPK, or Cdks. These effects apparently are not shared by all NSAIDs, since indomethacin failed to inhibit NF‐κB and AP‐1 activation as well as Erk and Cdk activity. In contrast, indomethacin was able to activate PPARγ, which was not affected by sodium salicylate or aspirin. The differences in cyclooxygenase‐independent mechanisms may have consequences for the specific use of these drugs in individual patients because additional effects may either enhance the efficacy or reduce the toxicity of the respective compounds.—Tegeder, I., Pfeilschifter, J., Geisslinger, G. Cyclooxygenase‐independent actions of cyclooxygenase inhibitors FASEB J. 15, 2057–2072 (2001)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · cited 1×
“pRb is present in quiescent cells in a hypophosphorylated state and sequesters E2F transcription factors (134).”
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Beighton, P., & Beighton, G. (1997) · The Person Behind the Syndrome · doi:10.1007/978-1-4471-0925-9_118 · Cited by 3,159
Cited by
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis
Roman-Blas, J. A., & Jimenez, S. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.04.008 · Cited by 688
Ibuprofen: pharmacology, efficacy and safety
Rainsford, K. D. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-0016-x · Cited by 667
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Diclofenac: an update on its mechanism of action and safety profile
Gan, T. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.486301 · Cited by 600
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477
Invited review: Inflammation during the transition to lactation: New adventures with an old flame
Bradford, B. J., Yuan, K., Farney, J. K., Mamedova, L. K., & Carpenter, A. J. (2015) · Journal of Dairy Science · doi:10.3168/jds.2015-9683 · Cited by 474
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Dixon, D. A., Tolley, N. D., King, P. H., Nabors, L. B., McIntyre, T. M., Zimmerman, G. A., & Prescott, S. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12973 · Cited by 444
De Larco, J. E., Wuertz, B. R. K., & Furcht, L. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0760 · Cited by 412
Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic Chondrocytes
van Buul, G. M., Koevoet, W. L. M., Kops, N., Bos, P. K., Verhaar, J. A. N., Weinans, H., Bernsen, M. R., & van Osch, G. J. V. M. (2011) · The American Journal of Sports Medicine · doi:10.1177/0363546511419278 · Cited by 407
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Self-citationAnti-inflammatory effects of aspirin and sodium salicylate
Amann, R., & Peskar, B. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01828-9 · Cited by 372
Aronoff, D. M., Canetti, C., & Peters-Golden, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.559 · Cited by 360
Fever and hypothermia in systemic inflammation: recent discoveries and revisions
Romanovsky, A. (2005) · Frontiers in Bioscience · doi:10.2741/1690 · Cited by 344
Takada, Y., Bhardwaj, A., Potdar, P., & Aggarwal, B. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208169 · Cited by 310
The Spinal Phospholipase-Cyclooxygenase-Prostanoid Cascade in Nociceptive Processing
Svensson, C. I., & Yaksh, T. L. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.092401.143905 · Cited by 302
The COX-2 pathway is essential during early stages of skeletal muscle regeneration
Bondesen, B. A., Mills, S. T., Kegley, K. M., & Pavlath, G. K. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00088.2004 · Cited by 300
Nonsteroidal Anti-Inflammatory Drugs and the Kidney
Hörl, W. H. (2010) · Pharmaceuticals · doi:10.3390/ph3072291 · Cited by 298
Acetylation of MEK2 and IκB kinase (IKK) activation loop residues by YopJ inhibits signaling
Mittal, R., Peak-Chew, S.-Y., & McMahon, H. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608995103 · Cited by 296
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 280
Burian, M., & Geisslinger, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.004 · Cited by 259
Self-citationGasparini, L., Ongini, E., & Wenk, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02743.x · Cited by 226
Sanjeewa, K. K. A., Fernando, I. P. S., Kim, E.-A., Ahn, G., Jee, Y., & Jeon, Y.-J. (2017) · Nutrition Research and Practice · doi:10.4162/nrp.2017.11.1.3 · Cited by 171
Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A
Bos, C. L., Kodach, L. L., van den Brink, G. R., Diks, S. H., van Santen, M. M., Richel, D. J., Peppelenbosch, M. P., & Hardwick, J. C. H. (2006) · Oncogene · doi:10.1038/sj.onc.1209658 · Cited by 156
Wang, J., Song, N., Jiang, H., Wang, J., & Xie, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.021 · Cited by 150
Kim, S.-J., Jeong, H.-J., Lee, K.-M., Myung, N.-Y., An, N.-H., Mo Yang, W., Kyu Park, S., Lee, H.-J., Hong, S.-H., Kim, H.-M., et al. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.11.001 · Cited by 116
Gao, J., Mfuh, A., Amako, Y., & Woo, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11639 · Cited by 102
Pharmacologic Inhibition of COX-1 and COX-2 in Influenza A Viral Infection in Mice
Carey, M. A., Bradbury, J. A., Rebolloso, Y. D., Graves, J. P., Zeldin, D. C., & Germolec, D. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011610 · Cited by 77
Müller-Decker, K. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9306-z · Cited by 73
“As a rule, the doses required to affect these targets are up to two orders of magnitude higher than those sufficient for COX inhibition [40, 41].”
Blais, V., Zhang, J., & Rivest, S. (2002) · Endocrinology · doi:10.1210/en.2002-220598 · Cited by 22
Metadata
- Authors
- Tegeder, I., Pfeilschifter, J., & Geisslinger, G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-10
- Volume
- 15
- Issue
- 12
- Pages
- 2057-2072
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1998232267
- Cited by
- 747
- References
- 199
- FWCI
- 30.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.